Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 8/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097929 | 0.96 | UTS2R (0.40) | UTS2RKMT2AMEN1LMNANPC1 | |
| SCHEMBL6095100 | 0.92 | UTS2R (0.46) | UTS2RHTR2AHTR2CKCNH2KMT2A | |
| SCHEMBL6096149 | 0.92 | UTS2R (0.50) | UTS2RHTR2CSLC5A7 | |
| SCHEMBL6093542 | 0.90 | UTS2R (0.37) | UTS2RKMT2ASLC5A7SMN1; SMN2GAA | |
| SCHEMBL6094514 | 0.88 | HRH3 (0.40) | KMT2AMEN1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL6093569 | 0.88 | UTS2R (0.46) | UTS2RKMT2AMEN1SLC5A7POLB | |
| SCHEMBL6741280 | 0.84 | UTS2R (0.55) | UTS2RHTR2AHTR2CKCNH2KMT2A | |
| SCHEMBL6839473 | 0.82 | UTS2R (0.45) | UTS2RHTR2AHTR2CKCNH2KMT2A | |
| SCHEMBL6193969 | 0.79 | UTS2R (0.40) | UTS2RKMT2AMEN1LMNANPC1 | |
| SCHEMBL6598823 | 0.79 | UTS2R (0.64) | UTS2RHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138224-A1 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138224-A1 | Pyrrolidine sulfonamides | UTS2R, PRSS2, PRSS8 | UTS2R 1/4885HTR2A 987/4885HTR2C 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.